Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05197881 · ClinicalTrials.gov registry record · NA

Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix

A NA study of Cervical Cancer by FIGO Stage 2018, sponsored by Varian, a Siemens Healthineers Company.

Recruiting
Registry status
NA
Development phase
125
Enrollment target
5
Study locations

NCT05197881 is a NA study of Cervical Cancer by FIGO Stage 2018 that is actively recruiting participants, run by Varian, a Siemens Healthineers Company. The registered enrollment target is 125 participants. The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05197881, a NA study of Cervical Cancer by FIGO Stage 2018, is actively recruiting participants, sponsored by Varian, a Siemens Healthineers Company.

RECRUITING
Registry status
NA
Development phase
125 participants
Enrollment target
5
Study locations

Study Summary

This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).

Interventions

  • DEVICE Varian Ethos Adaptive Radiation Therapy

Study Locations (5)

Alabama

  • University of Alabama Birmingham - Burmingham

Arkansas

  • University of Arkansas Medical Sciences - Little Rock

California

  • Moores Cancer Center at UC San Diego Health - La Jolla

Pennsylvania

  • Fox Chase Cancer Center - Philadelphia

Texas

  • University of Texas Southwestern - Dallas

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2022-05-03
Est. Completion 2030-09
Phase NA

What the Registry Record Tells You About NCT05197881

The ClinicalTrials.gov registry entry for NCT05197881 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Varian, a Siemens Healthineers Company, which has 16 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer by FIGO Stage 2018 appearing as the primary indexed condition, and to 1 intervention - of which Varian Ethos Adaptive Radiation Therapy is the first listed.

NCT05197881 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Arkansas, California.

Frequently Asked Questions

What is clinical trial NCT05197881 about?

NCT05197881 is a clinical study titled "Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix". This is a single-arm, prospective, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modul...

What is the current status of trial NCT05197881?

This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-05-03. Estimated completion is 2030-09.

What conditions does trial NCT05197881 study?

This clinical trial studies the following conditions: Cervical Cancer by FIGO Stage 2018.

What interventions are being tested in trial NCT05197881?

The interventions under investigation include: Varian Ethos Adaptive Radiation Therapy (DEVICE).

Who is sponsoring clinical trial NCT05197881?

This trial is sponsored by Varian, a Siemens Healthineers Company, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05197881 being conducted?

This trial has 5 study locations across Alabama, Arkansas, California, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.